"Naloxone Nanoparticle Compositions And Methods Thereof" in Patent Application Approval Process (USPTO 20230201369).
In: Drug Week, 2023-07-21, S. 1154-1154
serialPeriodical
Zugriff:
However, an oral formulation of naloxone is not currently available due to the oral bioavailability of naloxone being very low (e.g., estimated to be 0.9-2%). Keywords: Addiction Research; Analgesics; Antidotes; Cardiology; Cardiovascular Diseases and Conditions; Central Nervous System Agents; Drug Administration Routes; Drugs and Therapies; Emerging Technologies; Fentanyl Therapy; Health and Medicine; Hospitals; Hypertension; Mental Health; Naloxone Therapy; Nanoparticles; Nanotechnology; Narcotic Analgesics; Opioids; Oral Administration; Pain Medicine; Patent Application; Pharmaceuticals EN Addiction Research Analgesics Antidotes Cardiology Cardiovascular Diseases and Conditions Central Nervous System Agents Drug Administration Routes Drugs and Therapies Emerging Technologies Fentanyl Therapy Health and Medicine Hospitals Hypertension Mental Health Naloxone Therapy Nanoparticles Nanotechnology Narcotic Analgesics Opioids Oral Administration Pain Medicine Patent Application Pharmaceuticals 1154 1154 1 07/17/23 20230721 NES 230721 2023 JUL 17 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- A patent application by the inventors EITAN, Shoshana (College Station, TX, US); MAJETI, Naga Venkata Ravi Kumar (College Station, TX, US), filed on April 29, 2021, was made available online on June 29, 2023, according to news reporting originating from Washington, D.C., by NewsRx correspondents. Therefore, there exists a need for new compositions and methods that are efficacious in delivering naloxone to patients for therapeutic uses such as OIRD and other indications for which naloxone is utilized. Therefore, there exists a need for new compositions and methods that are efficacious in delivering naloxone to patients for therapeutic uses such as OIRD and other indications for which naloxone is utilized. [Extracted from the article]
Copyright of Drug Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
"Naloxone Nanoparticle Compositions And Methods Thereof" in Patent Application Approval Process (USPTO 20230201369).
|
---|---|
Zeitschrift: | Drug Week, 2023-07-21, S. 1154-1154 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1531-6440 (print) |
Schlagwort: |
|
Sonstiges: |
|